// App-Quantinova.ai

M4086 2016 AHA : Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis

Researchers

Presenter

  • Sylvia Haas

Principal Investigators

  • Alexander G.G Turpie

  • Silvia Kuhls

  • Susanne Hess

  • Thomas Evers

  • Pierre Amarenco

  • Paulus Kirchhof

  • A. John Camm

  • St Georges

Medical Centers

  • Univ of Birmingham and Sandwell and West Birmingham Hosp NHS Trust, Birmingham, United Kingdom

  • Univ of Connecticut, Hartford, CT

  • Univ of London, and Imperial Coll, London, United Kingdom

  • Paris-Diderot-Sorbonne Univ, Paris, France

  • Hamilton, McMaster Univ, ON, ON, Canada

  • Thrombosis Res Inst, Munich, Germany

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Bayer

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Non-valvular atrial fibrillation

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Xarelto

Outcome

  • N/A

Study Design

  • non interventional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved